This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Oct 2021

Alcami to manufacture PharmaTher’s proprietary ketamine products

The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances

Three weeks after Alcami announced it was investing an additional $31 million to expand its sterile CDMO operation in Charleston, SC to increase its fill-finish and lyophilisation capacity, the company has agreed to manufacture PharmaTher's proprietary ketamine products.

PharmaTher, a clinical-stage psychedelics biotech company, is building a specialty ketamine-based product pipeline to support its internal product pipeline.

Alcami will support PharmaTher’s global ketamine product development and commercialisation plans by supplying expertise in GMP sterile fill-finish manufacturing and controlled substances.

The ability to manufacture and supply ketamine products in different dosage forms enables PharmaTher to guarantee delivery on its product pipeline as well as form partnerships with research labs, ketamine clinics and pharmaceutical companies that are seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and commercialise specific ketamine products for new indications.

PharmaTher’s proprietary ketamine drug products are expected to be available for FDA Phase III clinical studies and commercial use during the latter half of 2022.

Mentioned Companies
View company profile

Related News